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Background: In machine learning classification methods developed for dementia studies, neuroimaging features, 
e.g. glucose consumption extracted from PET images, are often used to draw the border that differentiates 
normality from abnormality. However, these features are affected by the anatomical and metabolic variabilities 
present in the population, which acts as a confounding factor making the task of finding the frontier between 
normality and abnormality very challenging.  
Methods: To reduce the confounding impact of these variabilities when trying to distinguish disease versus 
normal ageing, we developed a method able to extract for each individual the signal characteristic of abnormality 
from 18F-FDG PET data. Instead of comparing the patient’s PET image to a population of healthy controls as 
usually done, this framework consists of creating a patient-specific model of healthy PET appearance, and 
comparing the patient’s PET image to the model via a Z-score [1]. The resulting voxel-wise Z-score map can be 
interpreted as an abnormality map, as it statistically evaluates the localised deviation of the patient-specific 
uptake with respect to the healthy uptake distribution. We applied this method to 298 ADNI2 subjects (103 
cognitively normal, 105 late MCI and 90 Alzheimer's disease subjects). The abnormality maps generated with 
the proposed method were then used as features to feed a classification algorithm based on linear support vector 
machines. We compared the classification results obtained using the abnormality maps to the classification 
results obtained using features from the native PET images, and using state-of-the-art Z-maps. 
Results: The balanced accuracy obtained with the proposed method when differentiating CN from late MCI and 
AD (80.5% and 91.6%, respectively) was found to be higher than the balanced accuracy obtained using PET 
SUVR values (78.3% and 88.9%) and the state-of-the-art Z-maps (78.7% and 89.6%) as features. The same trend 
was observed when differentiating amyloid positive from amyloid negative subjects (73.9% vs 71.5% and 71.4%). 
Conclusions: The high classification accuracy obtained when using the abnormality maps as features 
demonstrates that the proposed pipeline is able to extract for each individual the signal characteristic of dementia 
from FDG PET data. Instead of trying to find the frontier between normality and abnormality at the population 
level, by transporting the problem to the individual level, the proposed method appears to offer a more effective 
way of differentiating dementia stages. 
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Table: Balanced accuracy obtained when using PET standardised uptake value ratio (SUVR) images, state-of-
the-art Z-maps (obtained by comparing the patient’s PET image to a population of healthy controls), and 
proposed abnormality maps (obtained by comparing the patient’s PET image to a patient-specific model of 
healthy PET appearance) as features of the linear support vector machine classification algorithm. 
 
 CN vs AD CN vs LMCI Aß+ vs Aß- 
PET SUVR images 88.9% 78.3% 71.5% 
State-of-the-art Z-maps 89.6% 78.7% 71.4% 
Proposed abnormality maps 91.6% 80.5% 73.9% 
CN: cognitively normal – AD: Alzheimer’s disease – LMCI: late mild cognitive impairment – Aß+: amyloid 
positive (AV45 SUVR > 1.11) – Aß-: amyloid negative (AV45 SUVR < 1.11) 
